Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort studyCapsule Summary

• Main Authors: Xue Bai, MD (Author), Aleigha R. Lawless, BS (Author), Juliane A. Czapla, MS (Author), Stefanie C. Gerstberger, MD, PhD (Author), Benjamin C. Park, MD (Author), Seungyeon Jung, BA (Author), Rebecca Johnson, MN (Author), Naoya Yamazaki, MD, PhD (Author), Dai Ogata, MD, PhD (Author), Yoshiyasu Umeda, MD (Author), Caili Li, MB (Author), Jun Guo, MD, PhD (Author), Keith T. Flaherty, MD (Author), Yasuhiro Nakamura, MD, PhD (Author), Kenjiro Namikawa, MD, PhD (Author), Georgina V. Long, MBBS, PhD (Author), Alexander M. Menzies, MBBS, PhD (Author), Douglas B. Johnson, MD (Author), Ryan J. Sullivan, MD (Author), Genevieve M. Boland, MD, PhD (Author), Lu Si, MD (Author)
• Format: Book
• Published: Elsevier, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Anti-Program-Death-1 (PD-1) is a standard adjuvant therapy for patients with resected melanoma. We hypothesized that there are discrepancies in survival, recurrence pattern and toxicity to adjuvant PD-1 between different ethnicities and melanoma subtypes. Objective: We performed a multic...